8-K: DIH Holding US, Inc. Announces Strong First Quarter Fiscal 2025 Results with 24% Revenue Growth

DIH Holding US, Inc. reported a 24% increase in revenue for the first quarter of fiscal year 2025, reaching $16.2 million, driven by strong growth in device and service revenue.

Summary

• DIH Holding US, Inc. announced its financial results for the first quarter of fiscal year 2025, which ended on June 30, 2024.
• The company reported revenue of $16.2 million, a 24% increase compared to the same period last year.
• Device revenue grew by 18% to $12.3 million, while service revenue increased by 49% to $3.5 million.
• The company experienced significant growth in both the EMEA and Americas regions, with a 54% increase in revenue in both regions.
• Gross margin improved to 53.5%, a 12 percentage point increase year-over-year.
• Net loss was $0.6 million, an improvement of $2.3 million compared to the prior year period.
• DIH reiterated its full-year 2025 revenue guidance of $74 million to $77 million, representing a 15% to 20% growth over 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved gross margins, and a reduced net loss. The company's reaffirmation of its full-year guidance and positive management comments contribute to a high sentiment score.

Positives

• The company achieved a substantial 24% increase in overall revenue.
• Service revenue experienced a significant 49% growth, indicating strong demand for ongoing support and maintenance.
• The 12 percentage point improvement in gross margin to 53.5% demonstrates improved operational efficiency.
• The net loss decreased by $2.3 million, showing progress towards profitability.
• Strong revenue growth of 54% in both EMEA and the Americas regions indicates successful market penetration.
• The company has a broad portfolio of devices and an extensive range of services, positioning it as a total solution partner.

Negatives

• Selling, general, and administrative expenses increased by $2.8 million, or 48.2%, to $8.7 million.
• Research and development costs increased by $0.2 million, or 14.3%, to $1.6 million.
• The company still reported a net loss of $0.6 million for the quarter.
• Cash and cash equivalents decreased to $2.7 million as of June 30, 2024, from $3.2 million at the end of the previous quarter.

Risks

• The company's ability to achieve its projected revenue is subject to general economic, political, and business conditions.
• There is a risk that DIH may not realize the anticipated benefits of the recently completed business combination.
• The company's future performance depends on its ability to access additional debt or equity capital if needed.
• The company faces risks related to the successful and timely commercialization of its products.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expected results.

Future Outlook

The company expects full-year 2025 revenue to range between $74 million and $77 million, representing approximately 15%-20% growth over fiscal year 2024. They also plan to enrich their product solution offerings throughout the year.

Management Comments

• Jason Chen, Chairman and CEO of DIH, stated that he is very pleased with the company's performance in the first quarter of Fiscal Year 2025, showing significant progress over the same quarter last year.
• Jason Chen also expressed excitement that two of their major strategic markets, EMEA and the Americas, each achieved growth of 54% and that recurring service revenue grew by 49%.
• Jason Chen noted that the team has increased account penetration and enhanced productivity through workflow efficiencies, as reflected in the significant improvements in both gross margin and net income.
• Jason Chen stated that they will continue to enrich their product solution offerings throughout the year and remains excited about the significant growth opportunities ahead.

Industry Context

DIH operates in the neuro-rehabilitation and human performance research market, which is experiencing growth due to an aging population and increasing neurological disorders. The company's robotic rehabilitation solutions address the need for more intensive therapy and help to alleviate staffing shortages in hospitals and clinics. DIH is positioned as a consolidator in a fragmented industry.

Comparison to Industry Standards

• DIH's 24% revenue growth in Q1 2025 is strong compared to the estimated 27% CAGR for the rehabilitation robots market through 2027.
• The company's 54% growth in EMEA and the Americas is notable, suggesting successful market penetration compared to competitors.
• DIH's broad product portfolio, including robotic and VR-enabled movement systems, gives it a competitive edge over companies focused on single product categories, such as Ekso Bionics (EKSO) and ReWalk Robotics (LFWD).
• The company's 4,500+ installed devices and 1,800 customer accounts indicate a strong market presence compared to smaller emerging players.
• DIH's focus on both clinical and research applications, with products like CAREN and GRAIL, differentiates it from companies primarily focused on clinical rehabilitation.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved profitability positively.
• Employees may benefit from the company's growth and increased investment in personnel.
• Customers will have access to a broader range of rehabilitation solutions and services.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's improved financial performance favorably.

Next Steps

• The company will continue to enrich its product solution offerings throughout the year.
• DIH will focus on further penetrating existing accounts and entering new institutions.
• The company will leverage its global platforms and infrastructure to realize economies of scale.

Key Dates

Keywords

rehabilitation, robotic devices, physical therapy, neuro-rehabilitation, revenue growth, gross margin, medical devices, healthcare, EMEA, Americas